A
Accent Therapeutics
Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer
About Accent Therapeutics
Accent Therapeutics is a biopharmaceutical startup that is focused on developing innovative cancer treatments. The company's primary approach is to leverage its expertise in RNA-modifying protein (RMPs) biology, a field that studies how proteins interact with RNA to regulate cell functions. This approach allows Accent to identify and target specific vulnerabilities in cancer cells that are common across different types of cancer.
Read full description
The company's business model involves developing small molecule therapeutics, which are compounds that can enter cells easily due to their low molecular weight. These therapeutics are designed to inhibit the targets identified through their RMPs biology research, potentially offering a broad-spectrum solution for cancer patients.
Accent operates in the biopharmaceutical market, specifically in the oncology sector. Its clients are primarily patients living with cancer, particularly those with significant unmet medical needs. The company makes money by developing and commercializing its novel therapeutics. Once a therapeutic is developed, it can be patented and sold to healthcare providers or directly to patients.
The company prides itself on its team of experienced and collaborative professionals, who they refer to as ACCENTuators. These individuals are dedicated to translating extraordinary science into life-changing therapies for patients.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Lexington, United States
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 65.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Accent Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2024 | $75M | $300M | Mirae Asset Capital Life Science | ↗ |
| SERIES BOther financing | Apr 2020 | $63M | $252M | Atlas Venture · Droia Oncology Ventures · Timefolio Capital · Abbvie Biotech Ventures | ↗ |
Growth signals
Latest recorded traffic for Accent Therapeutics is 4K monthly website visits, up 29% over the last three months. Accent Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Atlas Venture
The Column Group
EcoR1 Capital
Droia Oncology Ventures- TCTimefolio Capital
Abbvie Biotech Ventures
The Mark Foundation for Cancer Research
Series B and later1 investor entered at this stage
Mirae Asset Capital Life Science
Other known investors2 additional known investors
Stanford University
The University of Chicago
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Accent Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Accent Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.